Avalo Therapeutics, Inc. (NASDAQ:AVTX – Get Free Report) was the recipient of a significant growth in short interest in September. As of September 15th, there was short interest totalling 59,500 shares, a growth of 38.1% from the August 31st total of 43,100 shares. Based on an average daily trading volume, of 16,200 shares, the short-interest ratio is presently 3.7 days. Currently, 0.6% of the shares of the company are sold short.
Institutional Trading of Avalo Therapeutics
A number of institutional investors and hedge funds have recently modified their holdings of AVTX. Logos Global Management LP purchased a new stake in Avalo Therapeutics during the 2nd quarter worth approximately $6,722,000. Affinity Asset Advisors LLC raised its stake in Avalo Therapeutics by 350.0% in the 2nd quarter. Affinity Asset Advisors LLC now owns 45,000 shares of the company’s stock valued at $561,000 after purchasing an additional 35,000 shares during the last quarter. Finally, Ikarian Capital LLC purchased a new position in Avalo Therapeutics in the 1st quarter valued at $1,015,000. Hedge funds and other institutional investors own 87.06% of the company’s stock.
Avalo Therapeutics Trading Up 0.5 %
Shares of Avalo Therapeutics stock traded up $0.05 during trading hours on Friday, reaching $9.40. The stock had a trading volume of 13,987 shares, compared to its average volume of 246,103. Avalo Therapeutics has a twelve month low of $3.95 and a twelve month high of $45.10. The stock’s 50 day moving average is $9.62 and its 200 day moving average is $11.22.
Avalo Therapeutics Company Profile
Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.
Featured Articles
- Five stocks we like better than Avalo Therapeutics
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Simon Property REIT: A Safe Bet for Growth and Steady Dividends
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- CarMax’s Impressive Rally: What Investors Should Watch Next
- How to Calculate Stock Profit
- MarketBeat Week in Review – 9/23 – 9/27
Receive News & Ratings for Avalo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.